Please use this identifier to cite or link to this item:
Title: Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
[Fernandez-Espartero, Cruz; Lopez Longo, Francisco J.] Hosp Univ Mostoles, Madrid, Spain.
[Peiteado, Diana] Hosp La Paz, Madrid, Spain.
[Pato, Esperanza; Diaz-Valle, David] Hosp Clin San Carlos, Madrid, Spain.
[Garcia-Arias, Miriam; Castaneda, Santos] Hosp Univ Princesa, IIS Princesa, Madrid, Spain.
[Javier Garcia-Gonzalez, A.] Hosp 12 Octubre, Inst Invest, Madrid, Spain.
[Almodovar Gonzalez, Raquel] Hosp Univ Fdn Alcorcon, Madrid, Spain.
[Muñoz Fernandez, Santiago] Hosp Univ Infanta Sofia, Madrid, Spain.
[Revenga Martinez, Marcelino; Jose Gonzalez-Lopez, Julio] Hosp Univ Ramon & Cajal, Madrid, Spain.
Issue Date: Dec-2019
Citation: Arthritis Rheumatol. 2019;(71)12:2081-2089
Abstract: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD).
PMID: 31237427
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. Infanta Sofía > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
31237427.pdf409.18 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.